semaglutide bmi 26 Effect of 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity - Wilkinson - 2023 - Obesity Prescribing semaglutide for weight loss

A standard weight-management titration reference (based on FDA-approved Wegovy protocol): Weeks 14: 0.25 mg once weekly Weeks 58: 0.5 mg once weekly Weeks 912: 1.0 mg once weekly Weeks 1316: 1.7 mg once weekly Week 17 onward: 2.4 mg once weekly (maintenance for obesity) For T2DM glycemic control, lower maintenance doses (0.52.0 mg weekly) are used per Ozempic labeling

Regular activity Combines medication effects with metabolism benefits

Originally FDA-approved for type 2 diabetes, Ozempic is the same semaglutide molecule as Wegovy but at different dose strengths (0.25mg, 0.5mg, 1mg, 2mg)

"Wegovy Savings Offer." NovoCare.com, 2025

Ozempic may cause serious side effects, including: Possible thyroid tumors, including cancer